According to data presented in a late-breaking oral presentation at the American Academy of Ophthalmology 2024 Annual Meeting ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic ...

Genentech, a member of the Roche (RHHBY), announced topline one-year results from the open-label, single-arm Phase IV ...

Roche (RHHBY) announced positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo ...

Enrollment goals for the U.S. part of the sutdy are 45% Black participants, 45% Hispanic participants and 10% Native American ...

事实上，随着越来越多的MNC介入以及国内头部药企的加码，行业竞争也会随之加剧，这其中自然会迸发出大量机会，同时也会 ...

A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected ...

Regeneron reported strong Q3 2023 results, driven by the growth of Dupixent and Libtayo, as by Eylea holding up against Vabysmo. Claims by Roche of market share gains have not translated into ...

Patients self-identified as members of the minority group that the study was designed to enroll, according to Jeremiah Brown, ...

近期，双抗领域疯狂“上分”。 图1. 依沃西与K药在治疗PD-L1表达阳性的非小细胞肺癌患者的临床对比（数据来源：公开资料） 先是在产品端。

2023年，尽管全球经济低迷，但也无法阻止药品市场规模持续增长。 据药智头条统计，2023年全球畅销药品中有10个销售额超过百亿美元，150个销售额 ...